Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLAAT3 | P53816 | 3/20 | 0.49 |
| ▸ | PLAAT5 | Q96KN8 | 3/20 | 0.49 |
| ▸ | PLAAT2 | Q9NWW9 | 3/20 | 0.49 |
| ▸ | PLAAT4 | Q9UL19 | 3/20 | 0.49 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.48 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.48 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.47 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.47 |
| ▸ | GFER | P55789 | 1/20 | 0.47 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.46 |
| ▸ | MEN1 | O00255 | 2/20 | 0.46 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.44 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.44 |
| ▸ | F2 | P00734 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2469668 | 0.95 | PLAAT3 (0.54) | PLAAT3PLAAT5PLAAT2PLAAT4CHRM5 | |
| SCHEMBL14327377 | 0.92 | PLAAT3 (0.48) | PLAAT3PLAAT5PLAAT2PLAAT4CHRM5 | |
| SCHEMBL2471846 | 0.92 | CHRM5 (0.50) | PLAAT3PLAAT5PLAAT2PLAAT4CHRM5 | |
| SCHEMBL2471734 | 0.92 | EPHX2 (0.53) | PLAAT3PLAAT5PLAAT2PLAAT4CHRM5 | |
| SCHEMBL2471543 | 0.90 | PLAAT3 (0.49) | PLAAT3PLAAT5PLAAT2PLAAT4CHRM5 | |
| SCHEMBL2468459 | 0.89 | CHRM5 (0.50) | PLAAT3PLAAT5PLAAT2PLAAT4CHRM5 | |
| SCHEMBL2469740 | 0.88 | TACR1 (0.48) | PLAAT3PLAAT5PLAAT2PLAAT4CHRM5 | |
| SCHEMBL10252957 | 0.87 | PLAAT3 (0.53) | PLAAT3PLAAT5PLAAT2PLAAT4CHRM5 | |
| SCHEMBL2471157 | 0.87 | GFER (0.52) | CHRM5CHRM3OPRM1OPRD1GFER | |
| SCHEMBL13688315 | 0.86 | CHRM5 (0.60) | CHRM5CHRM3GFEREPHX2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2371366-A1 | Heterocyclo inhibitors of potassium channel function | Bristol-Myers Squibb Company (US) | 2011-10-05 | — | — | EP | disclosed |
| US-20090312307-A1 | HETEROCYCLO INHIBITORS OF POTASSIUM CHANNEL FUNCTION | BRISTOL-MYERS SQUIBB COMPANY | 2009-12-17 | — | — | US | disclosed |
| US-20090312307-A1 | HETEROCYCLO INHIBITORS OF POTASSIUM CHANNEL FUNCTION | BRISTOL-MYERS SQUIBB COMPANY | 2009-12-17 | — | — | US | disclosed |
| US-7582654-B2 | Heterocyclo inhibitors of potassium channel function | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-09-01 | — | — | US | disclosed |
| US-7582654-B2 | Heterocyclo inhibitors of potassium channel function | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-09-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090312307-A1 | HETEROCYCLO INHIBITORS OF POTASSIUM CHANNEL FUNCTION | KCNJ2, KCNH2, KCNQ5 | PLAAT3 2175/4885PLAAT5 838/4885PLAAT2 1625/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.